BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32882850)

  • 1. Molecular Investigation on a Triple Negative Breast Cancer Xenograft Model Exposed to Proton Beams.
    Cammarata FP; Forte GI; Broggi G; Bravatà V; Minafra L; Pisciotta P; Calvaruso M; Tringali R; Tomasello B; Torrisi F; Petringa G; Cirrone GAP; Cuttone G; Acquaviva R; Caltabiano R; Russo G
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of cancerous progression by LISCH7 via direct stimulation of TGFB1 transcription in triple-negative breast cancer.
    Tang X; Zhou Y; Liu Y; Zhang W; Liu C; Yan C
    J Cell Biochem; 2020 Nov; 121(11):4642-4653. PubMed ID: 32048750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
    J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CPNE1 predicts poor prognosis and promotes tumorigenesis and radioresistance via the AKT singling pathway in triple-negative breast cancer.
    Shao Z; Ma X; Zhang Y; Sun Y; Lv W; He K; Xia R; Wang P; Gao X
    Mol Carcinog; 2020 May; 59(5):533-544. PubMed ID: 32181526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.
    Zheng X; Huang M; Xing L; Yang R; Wang X; Jiang R; Zhang L; Chen J
    Mol Cancer; 2020 Apr; 19(1):73. PubMed ID: 32264877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
    Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
    Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer.
    Xu X; Zhang Y; Jasper J; Lykken E; Alexander PB; Markowitz GJ; McDonnell DP; Li QJ; Wang XF
    Oncotarget; 2016 Apr; 7(15):20381-94. PubMed ID: 26967387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
    Tentler JJ; Lang J; Capasso A; Kim DJ; Benaim E; Lee YB; Eisen A; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Pitts TM; Pelanda R; Eckhardt SG; Diamond JR
    BMC Cancer; 2020 Nov; 20(1):1063. PubMed ID: 33148223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rhophilin-associated tail protein 1 promotes migration and metastasis in triple negative breast cancer via activation of RhoA.
    Liu Q; Huang X; Li Q; He L; Li S; Chen X; Ouyang Y; Wang X; Lin C
    FASEB J; 2020 Aug; 34(8):9959-9971. PubMed ID: 32427399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression.
    Kong Y; Yang L; Wei W; Lyu N; Zou Y; Gao G; Ou X; Xie X; Tang H
    Epigenomics; 2019 Aug; 11(10):1163-1176. PubMed ID: 31337246
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
    Chan C; Fonge H; Lam K; Reilly RM
    Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
    Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
    Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. hMAGEA2 promotes progression of breast cancer by regulating Akt and Erk1/2 pathways.
    Park S; Sung Y; Jeong J; Choi M; Lee J; Kwon W; Jang S; Park SJ; Kim HS; Lee MH; Kim DJ; Liu K; Kim SH; Dong Z; Ryoo ZY; Kim MO
    Oncotarget; 2017 Jun; 8(23):37115-37127. PubMed ID: 28415749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
    Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
    Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
    Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
    Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Putative tumor suppressor cytoglobin promotes aryl hydrocarbon receptor ligand-mediated triple negative breast cancer cell death.
    Rowland LK; Campbell PS; Mavingire N; Wooten JV; McLean L; Zylstra D; Thorne G; Daly D; Boyle K; Whang S; Unternaehrer J; Brantley EJ
    J Cell Biochem; 2019 Apr; 120(4):6004-6014. PubMed ID: 30450577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.